NRX Pharmaceuticals, Inc. (GETTEX:B1Q) Financings

NRX Pharmaceuticals, Inc.

Financings

RaiseDate
Strategic investment of restricted common stock
Closed: US$6.5M raised
Buyers: B Group Capital (Led a consortium of biotechnology investors purchasing approximately 3.9 million shares for $6.5 million)
Use of proceeds: Capital to reach expected regulatory inflection points
Aug 18, 2025
Debt financing
Update: US$7.8M
Buyers: Universal Capital, LLC ($7.8 million in debt financing)
Use of proceeds: HOPE Therapeutics clinic acquisitions, starting with Dura Medical, Kadima and NeuroSpa clinics
May 28, 2025
Strategic investment of series A Convertible Preferred Stock of HOPE Therapeutics
Announced: US$2.5M
Use of proceeds: Support the launch of HOPE's clinic network and the closing of its announced clinic acquisitions
Apr 3, 2025
Strategic investment of nRx common stock
Cancelled: US$2M · US$2.75 a share · Warrants at US$3 for 24 months
Buyers: Smith & Sauer ($2 million in NRx common stock at $2.75 per share); Smith and Sauer ($2.0 million in NRx common stock)
Use of proceeds: To advance the new drug applications for NRX-100 and NRX-101
Mar 17, 2025
Strategic investment of series A Preferred Stock of HOPE Therapeutics
Update: US$25M
Buyers: Smith & Sauer, LLC ($25 million equity purchases in HOPE Therapeutics Series A Preferred Stock); Smith and Sauer ($25 million in newly issued Series A Preferred Stock of HOPE)
Use of proceeds: To fund planned acquisitions of HOPE interventional psychiatry clinics in a nationwide rollup
Jan 28, 2025
Registered direct offering of common stock with common stock purchase warrants
Announced: US$3.5M · US$2.88 a share · Warrants at US$2.88
Buyers: Anson Funds
Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products
Jan 28, 2025
Senior secured convertible promissory notes
Announced: US$5.4M · Warrants at US$3.78
Buyers: Anson Funds
Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products
Jan 28, 2025

Read by 6ix AI from the company's releases